The September 21, 2017 amendments to the Patented Medicines (Notice of Compliance) Regulations
(see our article here
) introduced a new scheme for pharmaceutical patent linkage litigation in Canada. That scheme is now much closer to the US Hatch-Waxman scheme, but with remaining key differences, as shown in the chart below. A special thank you to Brian Coggio of Fish & Richardson for contributing the Hatch-Waxman details.
*revised January 2019